BIODELIVERY SCIENCES INTERNATIONAL INC Form 8-K October 15, 2012

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-K

# **CURRENT REPORT**

Pursuant to Section 13 or Section 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2012

# **BioDelivery Sciences International, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware** (State or other jurisdiction

001-31361 (Commission 35-2089858 (IRS Employer

of incorporation) File Number) Identification No.)


# Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 8-K

801 Corporate Center Drive, Suite #210

Raleigh, NC 27607
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: 919-582-9050

#### Not Applicable

(Former name or former address, if changed since last report)



- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- " Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- " Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

### Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 8-K

#### Item 8.01. Other Information.

On October 15, 2012, BioDelivery Sciences International, Inc. (the Company) issued a press release announcing the commercial launch of the Company s product, BREAKYL (fentanyl buccal film) in the European Union, which triggered a final milestone payment of \$2.5 million from Meda AB, the Company s commercial partner for BREAKYL in the European Union. The Company will also receive royalty on net sales of BREAKYL in the European Union. A copy of such press release is attached as Exhibit 99.1 hereto.

#### Item 9.01. Financial Statements and Exhibits.

- (d) Exhibits
- 99.1 Press release, dated October 15, 2012, announcing the commercial launch of the Company s product, BREAKYL (fentanyl buccal film) in the European Union.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.

#### **Cautionary Note Regarding Forward-Looking Statements**

This Current Report on Form 8-K, the press release included herein, and any statements of representatives and partners of BioDelivery Sciences International, Inc. (the Company ) related thereto contain, or may contain, among other things, certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company s plans, objectives, projections, expectations and intentions and other statements identified by words such as projects, may, will, could, would, should, believes, anticipate potential or similar expressions. These statements are based upon the current beliefs and expectations of the Company s management and are subject to significant risks and uncertainties, including those detailed in the Company s filings with the Securities and Exchange Commission. Actual results (including, without limitation, with respect to sales of BREAKYL in Europe and resulting royalty payments to the Company) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company s control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

# Edgar Filing: BIODELIVERY SCIENCES INTERNATIONAL INC - Form 8-K

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

October 15, 2012

BIODELIVERY SCIENCES INTERNATIONAL, INC.

By: /s/ James A. McNulty Name: James A. McNulty

Title: Secretary, Treasurer and Chief Financial Officer